Corxel announced this week the acquisition of VCT220, a small molecule GLP-1 agonist developed ... gut receptor targeted by Novo Nordisk’s Ozempic and Wegovy. Eli Lilly’s Mounjaro and Zepbound ...

Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...

Other companies, like Indiana-based Eli Lilly and California-based Structure Therapeutics, are also working on small-molecule obesity drugs, Traggis said. "For us, coming in a little bit later ...

To make the GLP-1 hormone "long-acting" her team found a way to attach a fatty acid to the molecule. She compares this structure to a steak — it's a one-two punch of protein and fat, protecting ...

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

This year saw several advancements across medicine, space technology, and AI that extend our knowledge in consequential ways.

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

India’s apex drug regulating authority, the Central Drugs Standard Control Organisation (CDSCO), has approved 19 new drugs so ...